For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …
Read More »Could “Smart” Insulin End Hypoglycemia? The Race Toward Glucose-Responsive Therapy
For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …
Read More »Where Do GLP-1 Drugs Fit in Modern Diabetes Treatment? Rethinking the Therapy Algorithm
Managing type 2 diabetes today can feel like solving a moving puzzle. With so many therapies available, how do clinicians decide what comes next? GLP-1 therapies have become a key part of today’s diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences. As treatment options evolve, …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.